» Articles » PMID: 20890272

Intrarenal Production of B-cell Survival Factors in Human Lupus Nephritis

Overview
Journal Mod Pathol
Specialty Pathology
Date 2010 Oct 5
PMID 20890272
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The B-cell survival factors APRIL and BLyS are important for B-cell maturation and activation and contribute to human autoimmune diseases. Interference with B-cell function by targeting these molecules is currently being investigated in large clinical trials for systemic lupus erythematosus. The local expression patterns of APRIL and BLyS have not been investigated in detail in kidneys with lupus nephritis. We studied the mRNA expression of APRIL, BLyS, and the corresponding receptors BCMA, TACI, and BAFF-R in microdissected human biopsies with proliferative lupus nephritis (n=25) and compared it with pretransplant biopsies of living donors (n=9). APRIL and BLyS mRNA levels were significantly higher in glomeruli of patients with proliferative lupus nephritis (12- and 30-fold, respectively). Tubulointerstitial expression of APRIL, BLyS, BCMA, and TACI was also significantly elevated. To localize the respective proteins in the kidney, APRIL, BLyS, and BAFF-R were studied by immunohistochemistry in renal biopsies with proliferative (n=21) or membranous (n=8) lupus nephritis. APRIL was prominently expressed in glomeruli with proliferative, but not membranous, lupus nephritis. The staining pattern was consistent with mesangial cells. A prominent accumulation of CD68-positive cells was present in glomeruli in association with APRIL expression. APRIL, BLyS, and BAFF-R were also expressed in interstitial inflammatory cell accumulation. This is the first study, which details local expression of APRIL and BLyS in glomeruli and tubulointerstitium of human proliferative lupus nephritis. This information might help define intrarenal effects of APRIL and BLyS inhibition in human lupus nephritis.

Citing Articles

Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy.

Li Z, Chen P, Zhang Y, Chen J, Zheng S, Li W Ren Fail. 2024; 46(2):2391069.

PMID: 39143819 PMC: 11328817. DOI: 10.1080/0886022X.2024.2391069.


Transcriptome Analysis of BAFF/BAFF-R System in Murine Nephrotoxic Serum Nephritis.

Mockel T, Boegel S, Schwarting A Int J Mol Sci. 2024; 25(10).

PMID: 38791453 PMC: 11121395. DOI: 10.3390/ijms25105415.


Uncovering lupus nephritis-specific genes and the potential of TNFRSF17-targeted immunotherapy: a high-throughput sequencing study.

Zou X, Yang M, Ye Z, Li T, Jiang Z, Xia Y Front Immunol. 2024; 15:1303611.

PMID: 38440734 PMC: 10909935. DOI: 10.3389/fimmu.2024.1303611.


Targeted therapies for lupus nephritis: Current perspectives and future directions.

Jia X, Lu Y, Zheng X, Tang R, Chen W Chin Med J (Engl). 2023; 137(1):34-43.

PMID: 38057972 PMC: 10766263. DOI: 10.1097/CM9.0000000000002959.


Telitacicept for autoimmune nephropathy.

Cai J, Gao D, Liu D, Liu Z Front Immunol. 2023; 14:1169084.

PMID: 37342346 PMC: 10277628. DOI: 10.3389/fimmu.2023.1169084.